Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

923907

Sigma-Aldrich

6F,C5-Pomalidomide-piperazine-piperidine-4-carbothioamide hydrochloride

Sinônimo(s):

2-(2,6-Dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidine-4-carbonothioyl)piperazin-1-yl)isoindoline-1,3-dione hydrochloride, Crosslinker–E3 ligase ligand conjugate, Protein degrader building block

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho

50 MG
R$ 2.671,00

R$ 2.671,00


Check Cart for Availability

Solicite uma grande encomenda

Selecione um tamanho

Alterar visualização
50 MG
R$ 2.671,00

About This Item

Fórmula empírica (Notação de Hill):
C23H26FN5O4S · xHCl
Peso molecular:
487.55 (free base basis)
Código UNSPSC:
12352101
NACRES:
NA.21

R$ 2.671,00


Check Cart for Availability

Solicite uma grande encomenda

ligand

6F,C5-Pomalidomide

Nível de qualidade

adequação da reação

reactivity: carboxyl reactive
reagent type: ligand-linker conjugate

grupo funcional

amine

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

O=C1C(N2C(C(C=C(F)C(N3CCN(C(C4CCNCC4)=S)CC3)=C5)=C5C2=O)=O)CCC(N1)=O.Cl

InChI

1S/C23H26FN5O4S.ClH/c24-16-11-14-15(22(33)29(21(14)32)17-1-2-19(30)26-20(17)31)12-18(16)27-7-9-28(10-8-27)23(34)13-3-5-25-6-4-13;/h11-13,17,25H,1-10H2,(H,26,30,31);1H

chave InChI

KFKOGFHONWLHKV-UHFFFAOYSA-N

Aplicação

Protein degrader building block 6F,C5-Pomalidomide-piperazine-piperidine-4-carbothioamide hydrochloride enables the synthesis of molecules for targeted protein degradation and PROTAC® (proteolysis-targeting chimeras) research. This conjugate contains a Cereblon (CRBN) recruiting ligand, a rigid linker, and a pendant amine for reactivity with a carboxylic acid on the target ligand. Because even slight alterations in ligands and crosslinkers can affect ternary complex formation between the target, E3 ligase, and degrader, many analogs are prepared to screen for optimal target degradation. When used with other protein degrader building blocks with a terminal amine, parallel synthesis can be used to more quickly generate degrader libraries that feature variation in crosslinker length, composition, and E3 ligase ligand.

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks

Informações legais

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

produto relacionado

Nº do produto
Descrição
Preços

Pictogramas

Health hazard

Palavra indicadora

Danger

Frases de perigo

Classificações de perigo

Repr. 1B

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of
Kedra Cyrus et al.
Molecular bioSystems, 7(2), 359-364 (2010-10-06)
Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Philipp M Cromm et al.
Cell chemical biology, 24(9), 1181-1190 (2017-06-27)
Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica